LAGUNA HILLS, Calif., Feb. 13, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology, announced today that it will make its first detailed public presentation of preclinical data relating to its new V2 Renal Denervation System on Saturday, February 18, 2012 at the TRenD Workshop 2012, in Frankfurt, Germany.
The presentation, titled "Percutaneous RF balloon-mediated renal denervation in under a minute: The V2 System by Vessix," will be made by James R. Margolis, M.D., a luminary in the field of interventional cardiology, during a session focused on emerging technologies for renal denervation.
Renal denervation is a percutaneous, catheter-based approach that disrupts renal sympathetic nerves whose hyperactivity leads to uncontrolled high blood pressure.
Dr. Margolis commented, "Vessix's pre-clinical data is the most robust I have seen in the field of renal denervation for hypertension. The data provides significant angiographic and histological evidence of safety and also effectiveness in reducing kidney norepinephrine levels a surrogate for reduction of blood pressure in humans. The Vessix RF balloon catheter technology promises to place a very familiar tool in the hands of interventionalists and allow therapy to be safely delivered in seconds. I look forward to seeing the results of the upcoming multi-center international clinical study set to begin in Europe later this month."
Vessix's V2 Renal Denervation System for the treatment of drug resistant hypertension is an over the wire balloon catheter with electrodes mounted on the exterior of the balloon to facilitate the delivery of RF inside the renal artery. The patented catheter connects to a proprietary low power bipolar RF generator. After inflation in the artery, the balloon catheter's RF energy is activated for 30 seconds resulting in the disruption of the renal nerves located in the adventitia that surround the renal artery.
About the Vessix V2 Renal Denervation System
- Therapy is delivered via a balloon catheter that is quite familiar to interventional cardiologists thereby increasing the usability and safety profile of the device.
- The V2 balloon catheter occludes blood flow to the renal artery during the 30 second RF therapy delivery allowing for directed and highly controlled flow of energy. Consequently, the V2 is significantly faster - by an order of magnitude - than the only other competitively marketed renal denervation system that takes approximately 30 minutes to deliver treatment to each renal artery.
- Rapid RF treatment time greatly increases the efficiency of the renal denervation procedure and promises additional safety benefits to the patient in terms of lower exposure to radiation, less use of contrast dye and lower renal toxicity.
About Vessix Vascular, Inc. Founded in 2003, Vessix is a venture backed privately-held pre-revenue stage company developing novel radiofrequency balloon catheter technology. The Company's initial product, the ZCath® System, has a CE Mark for use in reducing plaque in peripheral leg arteries. For more information on Vessix Vascular, please visit the Company's website at www.vessixvascular.com or contact Matt Clawson at Allen & Caron Inc at 949-474-4300 or via email at email@example.com.
Matt Clawson or
Len Hall (Media)
Allen & Caron Inc
SOURCE Vessix Vascular, Inc.